BEIJING, Nov. 22 (Xinhua) -- The 2023 China Pharmaceutical and Medical Device Enterprise R&D Index (PMDI) was unveiled at the China Pharmaceutical Industry Development Conference 2024, which was held on Nov. 16 in east China's Shanghai.
Photo shows Yang Shanhua, president of the Chinese Society of Pharmaceutical Accounting and chief accountant of Sinopharm Group, releasing the PMDI in Shanghai on Nov. 16, 2024.
The PMDI was compiled based on a comprehensive assessment system, with both focus on the width and depth of R&D investment and the quality and efficiency of R&D output, providing a thorough, objective, and scientific perspective for the R&D innovation trajectory of Chinese pharmaceutical and medical device companies.
Having been released for three times, the PMDI has witnessed a fluctuating growth with a positive trend during the past 11 years. The index stood at 68.50 in 2023, an increase of 1.65, compared to that of 2013, mirroring that the coordinated development of multiple dimensions of China's pharmaceutical and medical device enterprises' R&D efforts. Among these dimensions, the sub-index of R&D investment have showed the strongest performance, becoming the major driving force for the growth of PMDI.
In 2023, the PMDI dipped to 68.50 from 68.91 in 2022, indicating a decrease in the R&D sub-indexes of investment, achievement and support. However, the sub-index of R&D quality showed great resilience, standing at 66.26, a growth of 0.06 from 66.20 in 2022.
The PMDI was jointly released by China Center for International Economic Exchanges, China Economic Information Service, the Chinese Society of Pharmaceutical Accounting, the Academy of Digital Accounting and Tax at Beijing Jiaotong University, and China National Pharmaceutical Industry Information Center.
(Edited by Li Shimeng with Xinhua Silk Road, lishimeng@xinhua.org)
A single purchase
